Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER (+) breast cancer

Bone

Volumn 55, Issue 2, 2013, Pages 309-314

  Napoli, Nicola ^a,c   Rastelli, Antonella ^a   Ma, Cynthia ^a   Yarramaneni, Jayasree ^a   Vattikutti, Swapna ^a   Moskowitz, Gerard ^a   Giri, Tusar ^a   Mueller, Cheryl ^a   Kulkarny, Vibhati ^b   Qualls, Clifford ^b   Ellis, Matthew ^a   Armamento Villareal, Reina ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Aromatase inhibitors; Breast cancer; CYP19A1; Osteoporosis

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; AROMATASE; AROMATASE INHIBITOR; ESTRADIOL; VALINE; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; CYP19A1 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PEPTIDE;

ADULT; AGED; AROMATASE GENE; ARTICLE; BODY MASS; BONE DENSITY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTRADIOL BLOOD LEVEL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FRACTURE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; OSTEOLYSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; RACE DIFFERENCE; RADIOIMMUNOASSAY; RISK ASSESSMENT; BIOSYNTHESIS; BLOOD; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MIDDLE AGED; OSTEOPOROSIS; PHOTON ABSORPTIOMETRY; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; AGED, 80 AND OVER; AROMATASE; AROMATASE INHIBITORS; BONE DENSITY; BREAST NEOPLASMS; COLLAGEN TYPE I; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; PEPTIDES; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ESTROGEN;

EID: 84878143501     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.04.021     Document Type: Article

References (42)

1. Baum M., Budzar A.U., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359(9324):2131-2139.
2. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349(19):1793-1802.
3. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365(9453):60-62.
4. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350(11):1081-1092.
5. Bonneterre J., Thurlimann B., Robertson J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000, 18(22):3748-3757.
6. Mouridsen H., Sun Y., Gershanovich M., et al. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. Oncologist 2004, 9(5):489-496.
7. Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000, 18(22):3758-3767.
8. Forney J.P., Milewich L., Chen G.T., et al. Aromatization of androstenedione to estrone by human adipose tissue in vitro. Correlation with adipose tissue mass, age, and endometrial neoplasia. J Clin Endocrinol Metab 1981, 53(1):192-199.
9. Heshmati H.M., Khosla S., Robins S.P., O'Fallon W.M., Melton L.J., Riggs B.L. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 2002, 17(1):172-178.
10. Leelawattana R., Ziambaras K., Roodman-Weiss J., et al. The oxidative metabolism of estradiol conditions postmenopausal bone density and bone loss. J Bone Miner Res 2000, 15(12):2513-2520.
11. Rabaglio M., Sun Z., Price K.N., et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009, 20(9):1489-1498.
12. Thurlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353(26):2747-2757.
13. Lonning P.E., Geisler J., Krag L.E., et al. Effects of exemestane administered for 2years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005, 23(22):5126-5137.
14. Cheung A.M., Tile L., Cardew S., et al. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol 2012, 13(3):275-284.
15. Coleman R.E., Banks L.M., Girgis S.I., et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007, 8(2):119-127.
16. Bulun S.E., Takayama K., Suzuki T., Sasano H., Yilmaz B., Sebastian S. Organization of the human aromatase p450 (CYP19) gene. Semin Reprod Med 2004, 22(1):5-9.
17. Masi L., Becherini L., Gennari L., et al. Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk. J Clin Endocrinol Metab 2001, 86(5):2263-2269.
18. Somner J., McLellan S., Cheung J., et al. Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2004, 89(1):344-351.
19. Gennari L., Masi L., Merlotti D., et al. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab 2004, 89(6):2803-2810.
20. Riancho J.A., Valero C., Naranjo A., Morales D.J., Sanudo C., Zarrabeitia M.T. Identification of an aromatase haplotype that is associated with gene expression and postmenopausal osteoporosis. J Clin Endocrinol Metab 2007, 92(2):660-665.
21. Riancho J.A., Sanudo C., Valero C., et al. Association of the aromatase gene alleles with BMD: epidemiological and functional evidence. J Bone Miner Res 2009, 24(10):1709-1718.
22. Zarrabeitia M.T., Hernandez J.L., Valero C., et al. A common polymorphism in the 5'-untranslated region of the aromatase gene influences bone mass and fracture risk. Eur J Endocrinol 2004, 150(5):699-704.
23. Tofteng C.L., Kindmark A., Brandstrom H., et al. Polymorphisms in the CYP19 and AR genes-relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: the Danish Osteoporosis Prevention Study. Calcif Tissue Int 2004, 74(1):25-34.
24. Lorentzon M., Swanson C., Eriksson A.L., Mellstrom D., Ohlsson C. Polymorphisms in the aromatase gene predict areal BMD as a result of affected cortical bone size: the GOOD study. J Bone Miner Res 2006, 21(2):332-339.
25. Napoli N., Armamento-Villareal R. Effects of polymorphisms of the CYP450 enzyme genes on estrogen status and the risk for osteoporosis. Curr Pharmacogenomics 2007, 5:1-10.
26. Santen R.J., Brodie H., Simpson E.R., Siiteri P.K., Brodie A. History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev 2009 Jun, 30(4):343-375.
27. Grodin J.M., Siiteri P.K., MacDonald P.C. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973, 36(2):207-214.
28. Kristensen V.N., Harada N., Yoshimura N., et al. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 2000, 19(10):1329-1333.
29. Kristensen V.N., Andersen T.I., Lindblom A., Erikstein B., Magnus P., Borresen-Dale A.L. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 1998, 8(1):43-48.
30. Talbott K.E., Gammon M.D., Kibriya M.G., et al. A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk. Breast Cancer Res Treat 2008, 111(3):481-487.
31. Mononen N., Seppala E.H., Duggal P., et al. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res 2006, 66(2):743-747.
32. Cussenot O., Azzouzi A.R., Nicolaiew N., et al. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J Clin Oncol 2007, 25(24):3596-3602.
33. Beuten J., Gelfond J.A., Franke J.L., et al. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2009, 18(6):1869-1880.
34. Nawata H., Tanaka S., Tanaka S., et al. Aromatase in bone cell: association with osteoporosis in postmenopausal women. J Steroid Biochem Mol Biol 1995, 53(1-6):165-174.
35. Ziv-Gal A., Gallicchio L., Miller S.R., Zacur H.A., Flaws J.A. A genetic polymorphism in the CYP19A1 gene and the risk of hypertension among midlife women. Maturitas 2012, 71(1):70-75.
36. Hammoud A.O., Griffin J., Meikle A.W., Gibson M., Peterson C.M., Carrell D.T. Association of aromatase (TTTAn) repeat polymorphism length and the relationship between obesity and decreased sperm concentration. Hum Reprod 2010, 25(12):3146-3151.
37. Edwards T.L., Velez Edwards D.R., Villegas R., et al. HTR1B, ADIPOR1, PPARGC1A, and CYP19A1 and obesity in a cohort of Caucasians and African Americans: an evaluation of gene-environment interactions and candidate genes. Am J Epidemiol 2012, 175(1):11-21.
38. Dieudonne M.N., Pecquery R., Leneveu M.C., Giudicelli Y. Opposite effects of androgens and estrogens on adipogenesis in rat preadipocytes: evidence for sex and site-related specificities and possible involvement of insulin-like growth factor 1 receptor and peroxisome proliferator-activated receptor gamma2. Endocrinology 2000, 141(2):649-656.
39. Garcia-Casado Z., Guerrero-Zotano A., Llombart-Cussac A., et al. A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole. BMC Cancer 2010, 10:36.
40. Colomer R., Monzo M., Tusquets I., et al. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 2008, 14(3):811-816.
41. Mao J.J., Su H.I., Feng R., et al. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res 2011, 13(1):R8.
42. Wang L., Ellsworth K.A., Moon I., et al. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res 2010, 70(1):319-328.